

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N83A39D44F44EN.html>

Date: April 2022

Pages: 138

Price: US\$ 3,500.00 (Single User License)

ID: N83A39D44F44EN

Abstracts

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) pipeline Target constitutes close to 45 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 5, 1, 20 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease and Women's Health which include indications Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Non-Alcoholic Steatohepatitis (NASH), Chronic Kidney Disease (Chronic Renal Failure), Huntington Disease, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Focal Segmental Glomerulosclerosis (FSGS), Friedreich Ataxia, Inflammation, Inflammatory Bowel Disease, Mitochondrial Myopathy, Neurodegenerative Diseases, Osteoarthritis, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Retinal Degeneration, Sickle Cell Disease, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes, Acne Vulgaris, Acute Renal Failure (ARF) (Acute Kidney Injury), Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), Age Related Macular Degeneration, Alport Syndrome, Asbestosis, Aspiration Pneumonitis, Atherosclerosis, Beta Thalassaemia, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Coronavirus Disease 2019 (COVID-19), Dementia, Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Epidermolysis Bullosa, Epilepsy, Fibrosis, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Idiopathic Pulmonary Fibrosis, IgA Nephropathy (Berger's Disease), Ischemia Reperfusion Injury, Ischemic Stroke, Juvenile Myelomonocytic Leukemia (JMML), Kennedy's Disease (Spinal and Bulbar Muscular Atrophy), Kidney Disease (Nephropathy), Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoporosis, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Polycystic Kidney Disease, Polycystic Ovarian Syndrome, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Fibrosis, Pulmonary Hypertension, Refractory Medulloblastoma, Retinopathy, Secondary Progressive Multiple Sclerosis (SPMS), Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Drugs In Development, 2022, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics, complete with analysis by indications, stage of development,

mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or

Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Overview

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Companies Involved in Therapeutics Development

AKL Research and Development Ltd

Annji Pharmaceutical Co Ltd

Anteris Bio

Arbor Pharmaceuticals LLC

Bach Pharma Inc

Bayer AG

BioApex sro

Biogen Inc

Biotoxtech Co Ltd

C4X Discovery Holdings Plc

Cellix Bio Pvt Ltd

Complexa Inc

Cureveda LLC

Daiichi Sankyo Co Ltd

Erganeo

Evgen Pharma Plc

Haisco Pharmaceutical Group Co Ltd

Immungenetics AG

Ixchel Pharma LLC

Lignamed LLC

Mariposa Therapeutics Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rescue Therapeutics Inc

Scohia Pharma Inc

Sulfateq BV

Vitalis LLC

Vividion Therapeutics Inc

vTv Therapeutics Inc

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid
Derived 2 Like 2 or NFE2L2 or NRF2) - Drug Profiles

(apocynin + paeonol) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + dimethyl fumarate) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + diroximel fumarate) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + monomethyl fumarate) - Drug Profile

Product Description

Mechanism Of Action

History of Events

ALZ-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ALZ-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BA-1521 - Drug Profile

Product Description

Mechanism Of Action
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
History of Events
BTT-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
C4X-6746 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CLXNEU-06 - Drug Profile
Product Description
Mechanism Of Action
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DH-404 - Drug Profile
Product Description
Mechanism Of Action
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
dioximel fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events

HPP-3033 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HPP-971 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HSK-36212 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HYCO-13 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IXC-103 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LGM-2605 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MG-132 - Drug Profile

Product Description

Mechanism Of Action

MIND-4 - Drug Profile

Product Description

Mechanism Of Action

History of Events

monosodium luminol - Drug Profile

Product Description

Mechanism Of Action

History of Events

nifurtimox - Drug Profile

Product Description

Mechanism Of Action

History of Events

omaveloxolone - Drug Profile

Product Description

Mechanism Of Action

History of Events

RS-9 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RTI-79 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SCO-116 - Drug Profile

Product Description

Mechanism Of Action

SFX-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SFX-02 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate NFE2L2 for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Activate NFE2L2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Activate NRF2 for Chronic Kidney Disease and Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Nrf2 for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

SUL-121 - Drug Profile

Product Description

Mechanism Of Action

TBE-31 - Drug Profile

Product Description

Mechanism Of Action

tepilamide fumarate - Drug Profile

Product Description

Mechanism Of Action

History of Events

TFM-735 - Drug Profile

Product Description

Mechanism Of Action

VCB-102 - Drug Profile

Product Description

Mechanism Of Action

VEDA-1209 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Dormant Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Discontinued Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Product Development Milestones

Featured News & Press Releases

Apr 04, 2022: Biogen announces new update on VUMERITY at AAN 2022

Mar 31, 2022: Reata Pharmaceuticals completes rolling submission of new drug application for Omaveloxolone for the treatment of patients with Friedreich's Ataxia

Mar 17, 2022: Viartis defeats Biogen's attempt to Revive Tecfidera patent

Mar 07, 2022: Evgen Pharma : Expansion of collaboration with the Manchester Breast Centre

Feb 25, 2022: Reata Pharmaceuticals receives complete response letter from the FDA for bardoxolone for the treatment of patients with chronic kidney disease caused by Alport syndrome

Feb 15, 2022: Haisco's announcement on obtaining the "Notice of Acceptance" for clinical trial application of innovative drug HSK36212 capsules

Jan 31, 2022: Reata Pharmaceuticals initiates rolling submission of new drug application with U.S. FDA for Omaveloxolone for the treatment of patients with Friedreich's ataxia

Jan 11, 2022: Evgen Pharma: Progress with UK and US regulators for 2022 clinical trials

Dec 14, 2021: Imara presents preclinical data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 08, 2021: Reata Pharmaceuticals announces outcome of FDA advisory committee meeting of Bardoxolone for the treatment of patients with chronic kidney disease caused by alport syndrome

Dec 08, 2021: Reata Pharmaceuticals stock trading halted; FDA Advisory Committee to discuss bardoxolone for the treatment of patients with chronic kidney disease caused by Alport Syndrome

Dec 01, 2021: Viartis wins Federal circuit court appeal upholding district court decision invalidating Biogen's Tecfidera Patent

Nov 18, 2021: Reata Pharmaceuticals receives Fast Track Designation from the FDA for Omaveloxolone for the treatment of Friedreich's Ataxia

Nov 16, 2021: The European Commission grants marketing authorization for VUMERITY (diroximel fumarate) as oral treatment for relapsing-remitting multiple sclerosis

Nov 10, 2021: Evgen Pharma: Publication of data on SFX-01 in glioblastoma
Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AKL Research and Development Ltd, 2022

Pipeline by Annji Pharmaceutical Co Ltd, 2022

Pipeline by Anteris Bio, 2022

Pipeline by Arbor Pharmaceuticals LLC, 2022

Pipeline by Bach Pharma Inc, 2022

Pipeline by Bayer AG, 2022

Pipeline by BioApex sro, 2022

Pipeline by Biogen Inc, 2022

Pipeline by Biototech Co Ltd, 2022

Pipeline by C4X Discovery Holdings Plc, 2022

Pipeline by Cellix Bio Pvt Ltd, 2022

Pipeline by Complexa Inc, 2022

Pipeline by Cureveda LLC, 2022

Pipeline by Daiichi Sankyo Co Ltd, 2022

Pipeline by Erganeo, 2022

Pipeline by Evgen Pharma Plc, 2022

Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Pipeline by Immugenetics AG, 2022

Pipeline by Ixchel Pharma LLC, 2022

Pipeline by Lignamed LLC, 2022

Pipeline by Mariposa Therapeutics Ltd, 2022

Pipeline by Mochida Pharmaceutical Co Ltd, 2022

Pipeline by Reata Pharmaceuticals Inc, 2022

Pipeline by Rescue Therapeutics Inc, 2022

Pipeline by Scohia Pharma Inc, 2022

Pipeline by Sulfateq BV, 2022

Pipeline by Vitalis LLC, 2022

Pipeline by Vividion Therapeutics Inc, 2022

Pipeline by vTv Therapeutics Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N83A39D44F44EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N83A39D44F44EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970